Rapamycin (Sirolimus) 化学構造
分子量: 914.18

高品質保証

文献中の引用(62)

カスタマーフィードバック(12)

Quality Control & MSDS

製品説明

  • Compare mTOR Inhibitors
    mTOR製品生物活性の比較
  • 研究分野
  • Combination Therapy
    併用療法

製品の説明

生物活性

製品説明 Rapamycin (Sirolimus) は、特定のmTOR阻害剤で、IC50 が ~0.1 nMです。
ターゲット

mTOR

IC50

~0.1 nM [1]

In vitro試験 Rapamycin inhibits endogenous mTOR activity in HEK293 cells with IC50 of ~0.1 nM, more potently than iRap and AP21967 with IC50 of ~5 nM and ~10 nM, respectively. [1] In Saccharomyces cerevisiae, Rapamycin treatment induces a severe G1/S cell cycle arrest and inhibition of translation initiation to levels below 20% of control. [2] Rapamycin significantly inhibits the cell viability of T98G and U87-MG in a dose-dependent manner with IC50 of 2 nM and 1 μM, respectively, while displaying little activity against U373-MG cells with IC50 of >25 μM despite the similar extent of the inhibition of mTOR signaling. Rapamycin (100 nM) induces G1 arrest and autophagy but not apoptosis in Rapamycin-sensitive U87-MG and T98G cells by inhibiting the function of mTOR. [3]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
HT-29 NWPMPWdwS3m2b4TvfIlkKEG|c3H5 MYqxNEBvVQ>? M4j4[VczKGh? MVfEUXNQ MnfDVI91\W62aXH0[ZMh[2GvcITveIhm[2mwLXnu[JVk\WRiY4n0c5RwgGmlaYT5 MVuyOFkxODh5Mx?=
HT-29 MnfhR5l1d3SxeHnjJGF{e2G7 MUWxNEBvVQ>? NXzi[pp2PzJiaB?= M1P0VmROW09? NIXCWlJRd3SnboTpZZRmeyCmaXfpeI95cW5vaX7keYNm\CCleYTveI95cWOrdIm= M3ri[|I1QTByOEez
HT-29 MXPDfZRwfG:6aXOgRZN{[Xl? NH:3WXAyOCCwTR?= NGLBXGs4OiCq M{\5UGROW09? Mn3xVI91\W62aXH0[ZMhPS2obIXvdo92emGlaXytbY5lfWOnZDDjfZRwfG:6aXPpeJk> NV3ZUnN[OjR7MEC4O|M>
PC3 MkPqT4lv[XOnIFHzd4F6 NYSwW3FHOTByIH7N MoDBNUBp MmfHSG1UVw>? NGPOZ|ZRd3SnboTsfUBqdmirYnn0d{BuXE:ULX3l[IlifGWmIGO2JJBpd3OyaH;yfYxifGmxbjD3bZRpKEmFNUCgc4YhRDFyIH7NMi=> M1;meVIyQTd6Nkiz
PC3 NYfOfY9{U2mwYYPlJGF{e2G7 M3TT[lExOCCwTR?= NFrZVI8yKGh? MnnlSG1UVw>? NWnaZnZxTG:nczDuc5QhcW6qaXLpeEBuXE:ULX3l[IlifGWmIFHreEBxcG:|cHjvdplt[XSrb36= NEW5WIYzOTl5OE[4Ny=>
PC3 M1zURWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmPoNU42KM7:TR?= NIC0ZXgyKGh? MXzEUXNQ NEjSPFhKdmS3Y3XzJIFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iUFOzJINmdGy|IIfpeIghUUN3MDDv[kA9OTBibl2= MYmyNVk4QDZ6Mx?=
HEK293 NHW4UVNHfW6ldHnvckBCe3OjeR?= NEfwXGQyODBibl2= MlTWPEBp NHPLZ4pFVVOR NUC2OYpJUW6qaXLpeJMhXFCDLXnu[JVk\WRiZHXndoFl[XSrb36gc4YhWGSlZESge4l1cCCHQ{WwJI9nKDVyIH7N NV3NSVU{OjF3M{mzNFE>
BT-20 M1;wWGtqdmG|ZTDBd5NigQ>? M1TQWFIxKM7:TR?= MkTHSG1UVw>? MlTrSI9meyCwb4SgbY5pcWKrdDDtWG9TSzJiZHXw[Y5l\W62IIDBb3QhWzR5MzDwbI9{eGixconsZZRqd25? NGTyNJUzOTN3M{W1NS=>
U937 NGDLeHdCdnSrYnHjeIVzcWGuIFHzd4F6 M4POS|UxKM7:TR?= MkDEOFghcA>? MYrEUXNQ MnfPTY5lfWOnczDhcpRq[mGldHXybYFtKGGldHn2bZR6KGGpYXnud5Qhf2muZDD0fZBmKEynZ3nvcoVtdGFicH7leY1weGirbHGgVIhqdGGmZXzwbIliNTFiSmKzNkBqdiCXOUO3JINmdGy| MofPNlEyPDJzME[=
U937 NGjFbZpCdnSrYnHjeIVzcWGuIFHzd4F6 MWq1NEDPxE1? NF65RVc1QCCq MWLEUXNQ NWrYXJk4TG:nczDuc5QhcW6mdXPlJIFvfGmkYXP0[ZJq[WxiYXP0bZZqfHliYXfhbY5{fCCPSWCgdJJwfGWrbj3k[YZq[2mnboSgUIVocW:wZXzsZUBxdmW3bX;wbIlt[SCMUkOyMVIhcW5iVUmzO{Bk\Wyucx?= MX[yNVE1OjFyNh?=
U937 NXy1VpdYSW62aXLhZ5RmemmjbDDBd5NigQ>? MlflOVAh|ryP MmjEOFghcA>? MVrEUXNQ M3nnTWRw\XNibn;0JIlv\HWlZTDhcpRq[mGldHXybYFtKGGldHn2bZR6KGGpYXnud5QhTXOlaHXybYNpcWFiY3;sbUBJSjFyMTDpckBWQTN5IHPlcIx{ NHToSZkzOTF2MkGwOi=>
MCF-7 MlPVRZV1d3CqYXf5JGF{e2G7 NYnrPXU4OzBibl2= M{fRUlQhcA>? M3HWfWROW09? MnXGTY5lfWOnczDheZRweGijZ4m= NVHQXmlLOjByMkixN|Q>
U87MG MUnLbY5ie2ViQYPzZZk> NVLoNlRjOSEQvF2= NH3EXYE3KGh? Ml7jSG1UVw>? NYjnVHdjWG:2ZX70cJkhcW6qaXLpeJMhdVSRUj3t[YRq[XSnZDDTOkBxcG:|cHjvdplt[XSrb36= Mk\VNVk5PDh2MES=
U87MG Mnu1T4lv[XOnIFHzd4F6 MXWxJO69VQ>? MWi2JIg> NUjNV4xGTE2VTx?= NH22TIFRd3SnboTsfUBqdmirYnn0d{A1TUKSMTjUO|AqKHCqb4PwbI9zgWyjdHnvci=> MnvVNVk5PDh2MES=
U87MG M2WwZmtqdmG|ZTDBd5NigQ>? M4X2[FEh|ryP Ml;DOkBp NWjnVYI6TE2VTx?= M3LKd2Rw\XNibn;0JIlvcGmkaYSgcXRQWi2vZXTpZZRm\CCDa4SgdIhwe3Cqb4L5cIF1cW:w NEjjc44yQTh2OESwOC=>
U87MG NVrPbGJ4U2mwYYPlJGF{e2G7 M{jXdVEh|ryP MojKOkBp Mmj5SG1UVw>? NYHSZW9CTG:nczDuc5QhcW6qaXLpeEBRNTSHQmCxLHQ{Py92NjmgdIhwe3Cqb4L5cIF1cW:w MYmxPVg1QDRyNB?=
COS7 cells expressing EGFP-HDQ74/rheb Mn;qRZV1d3CqYXf5JGF{e2G7 NVPRWlV4OC5{IN88US=> MmC2NlQhcA>? MXjEUXNQ M2W0[Wlv\HWlZYOgZZV1d3CqYXf5 NXfyNHdNOTh|OUG5OFk>
COS7 cells expressing EGFP-LC3 Mn;mRZV1d3CqYXf5JGF{e2G7 MlLhNE4zKM7:TR?= NHnENIczPCCq MmTOSG1UVw>? NYLoN|loUW6mdXPld{BifXSxcHjh[5k> NX\o[3diOTh|OUG5OFk>
H4 MmL3SpVv[3Srb36gRZN{[Xl? NWK2ZYd[OC5{IN88US=> MVSyOEBp M1fmb2ROW09? NH\Hd|lKdmO{ZXHz[ZMhfGinIILheIlwKG:oIHzp[4h1KGOqYXnuJFMhe3WkdX7peEAzKHSxIHzp[4h1KGOqYXnuJFMhe3WkdX7peEAyKGmwIHj1cYFvKEh2IHPlcIx{ Ml3KNVgxOjR3OES=
HeLa NFzNR2dHfW6ldHnvckBCe3OjeR?= MojmNVAxKG6P NUPWc256OzZiaB?= MnLKSG1UVw>? MkXtTY5lfWOnczDGVmIhUzJyOUXQMEBVOjB7OFysJHczOTBzRjDteZRidnRvdXLpdZVqfGmwQzDpcpRmemGldHnvci=> MnrwNVc2PjN|OEW=
HeLa M3fQcmZ2dmO2aX;uJGF{e2G7 NYi0WIxJOTByIH7N M2HjPFM3KGh? NGmzO5pFVVOR MnzzTY5lfWOnczDGVmIhXzJzMEHGJI12fGGwdD31ZolyfWm2aX7DJIlvfGW{YXP0bY9v M4GwelE4PTZ|M{i1
HeLa MkTrSpVv[3Srb36gRZN{[Xl? NITk[GEyODBibl2= MVWzOkBp M2HKWGROW09? NI\kVIpKdmS3Y3XzJGZTSi2IS1LQJINwdXCuZYigbY51\XKjY4Tpc44> M2mwcFE4PTZ|M{i1
SYF MlrwSpVv[3Srb36gRZN{[Xl? MlXGNVAxKG6P NEX3dIUzPCCq M1jTcWROW09? Mnn2TY5lfWOnczDGVmIuTkuEUDDjc41xdGW6IHnueIVz[WO2aX;u M4DWbFE4PTZ|M{i1
SYF NHjMfpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHvlN5MyODBibl2= Mm\DNlQhcA>? MlLHSG1UVw>? MlL6TY5lfWOnczDhcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IGPZSkBk\Wyucx?= MlK1NVc2PjN|OEW=
HEK293T NYTESYg3SW62aY\pdoFtKEG|c3H5 Mn;aNUBvVQ>? Mle5OEBl NVXTWGhHTE2VTx?= MV3JcoR2[2W|IHHueIl3cXKjbDDhZ5Rqfmm2eTDh[4FqdnO2IFjJWlEhWjVid3n0bEBGSzVyIH;mJFAvOSCwTR?= MYOxO|Q5PTVyMR?=
HEK293T NYfON|N7SW62aY\pdoFtKEG|c3H5 MXWxJI5O NH7zdnc1KGR? MUPEUXNQ NIGxN41KdmS3Y3XzJIFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGhKXjFiWESge4l1cCCHQ{WwJI9nKDBwMzDuUS=> MkH4NVc1QDV3MEG=
PBMC MWXGeY5kfGmxbjDBd5NigQ>? NYH3V4duOSCwTR?= NH3iSYkyPCCm NXH5W4R7TE2VTx?= NIewcnlT\WS3Y3XzJGNEWjViZHXud4l1gQ>? MofKNVc1QDV3MEG=
PBMC MUTGeY5kfGmxbjDBd5NigQ>? M1PGelEhdk1? M1zGNVE1KGR? M2TmUWROW09? MVvEc4V{KG6xdDDh[oZm[3RiQ2jDVlQh\GWwc3n0fS=> NVyyPFZkOTd2OEW1NFE>
HEK293 cells Mni1T4lv[XOnIFHzd4F6 MVe1NEBvVQ>? MU[0OUBucW5? MWHEUXNQ NHT6bnVKdmirYnn0d{BuXE:UIHvpcoF{\SCjY4Tpeol1gSC5aYToJGlEPTBib3[gNE4yKG6P MoD3NVc{PTB7NUO=
Drosophila melanogaster S2 cells transfected with N-luc and C-luc MX3GeY5kfGmxbjDBd5NigQ>? M4nPWlExOCCwTR?= MoLnOEBp MY\EUXNQ MVXJcoR2[2W|IHz1Z4ln\XKjc3WgdJJwfGWrbjD0doFvey2|cHzpZ4lv\yCrbjDEdo9{d3CqaXzhJI1mdGGwb3fhd5RmeiCVMjDj[YxteyC2cnHud4Zm[3SnZDD3bZRpKE5vbIXjJIFv\CCFLXz1Zy=> NGLSNVgyPzF{OEK2Ni=>
Human mixed lymphocyte MoLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWnwPXB5PSCwTR?= NY[0cGk5TE2VTx?= NVrFZ4hvUUN3ME2xMlYhdk1w NEfoUlUyPjF6NUi2OS=>
Lewis rat lymph node cells M2HNbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXXzc|NwPSEQvF2= M334T2ROW09? NXnx[3QzUUN3ME2yMlYh|ryP M3jmZVE3OTh3OE[1
cells from the thymus of normal BALB/c mice MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXOxNEBvVQ>? MWC3NkBp MljPSG1UVw>? NFPYPWdKdmirYnn0d{BtgW2yaH;wdo9tcW[ncnH0bY9vKCiOQV[pJJdqfGhiSVO1NEBw\iB|IH7N NHrYOmcyODB{MUm0PC=>
MRK-nu-1 NXL5eppKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTBwOES1JJBO NGnvRY9USU6JRWK=
OCUB-M M3PxUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{nWNmlEPTB;NT6yOEBxVQ>? NFHoZpdUSU6JRWK=
SF539 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV60RYFrUUN3ME2xNU43KHCP NGS1Rm9USU6JRWK=
ES4 NHfh[GVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUK4TI42UUN3ME2yNU42KHCP NHLFemhUSU6JRWK=
RL95-2 Mn70S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTFyNzDwUS=> NH7UW3ZUSU6JRWK=
LC-2-ad M{H0[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTR{MzDwUS=> M3yzVnNCVkeHUh?=
Daudi NWjZ[YlyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnGzTWM2OD12M{SgdG0> MkLRV2FPT0WU
NTERA-S-cl-D1 Ml7mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTR2MzDwUS=> NIrkcWpUSU6JRWK=
OS-RC-2 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHrqVFdKSzVyPU[1NkBxVQ>? NX;BPXprW0GQR1XS
VA-ES-BJ MofzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTd{MzDwUS=> MVTTRW5ITVJ?
GR-ST M3vJOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTh2NjDwUS=> M3PUeXNCVkeHUh?=
SW872 M3zxeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHjVbotKSzVyPUi0OkBxVQ>? MYnTRW5ITVJ?
NOS-1 NWPuc5VMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnHQTWM2OD16N{GgdG0> NV\XR5JjW0GQR1XS
MC116 MnPqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXLoR29SUUN3ME25PFUheE1? NUS0ZlBQW0GQR1XS
NCI-H1355 Mnq4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmrTTWM2OD1zLkCxJI5O NUDPW4ZoW0GQR1XS
RPMI-8226 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX;JUnRyUUN3ME2xMlE6KG6P NXrQc29nW0GQR1XS
TE-15 MlPaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\XSW1KSzVyPUGuN|Yhdk1? NUXTb4U1W0GQR1XS
Ramos-2G6-4C10 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFToeYpKSzVyPUGuOFYhdk1? NV;SWpNWW0GQR1XS
KU812 MmjjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWDBS3VZUUN3ME2yMlAyKG6P M3;6dHNCVkeHUh?=
EW-1 MkHDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2XZSWlEPTB;Mj6xO{BvVQ>? MnO1V2FPT0WU
KS-1 M3Syd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{ftR2lEPTB;Mj60OUBvVQ>? MXPTRW5ITVJ?
SK-LMS-1 MnqwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3n6VmlEPTB;Mj60PUBvVQ>? NHS2cmhUSU6JRWK=
TGBC1TKB MnTvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTJwNkmgcm0> NU[y[mF[W0GQR1XS
TE-6 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTJwN{egcm0> MofxV2FPT0WU
ETK-1 NETufFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTJwOEKgcm0> MYfTRW5ITVJ?
BE-13 MnP3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M17R[2lEPTB;Mj65PUBvVQ>? M{i3TXNCVkeHUh?=
A3-KAW NWq4U5dKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlnyTWM2OD1{Lkm5JI5O MnHGV2FPT0WU
TE-10 NWXiR3VOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\0eHRKSzVyPUOuN{BvVQ>? M2TDSnNCVkeHUh?=
DOHH-2 M4P4cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTNwM{Wgcm0> Mm[5V2FPT0WU
ES6 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M33NTmlEPTB;Mz60N{BvVQ>? M4rle3NCVkeHUh?=
OPM-2 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTRwMUWgcm0> NX[1TIdWW0GQR1XS
SH-4 M4XZd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTRwM{Sgcm0> M{HUenNCVkeHUh?=
NB13 M3nWNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2PJO2lEPTB;ND6zOkBvVQ>? MoLaV2FPT0WU
HUTU-80 NVr1XXM{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlPsTWM2OD12LkSyJI5O NUnJXFRMW0GQR1XS
CCRF-CEM MkTvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzQNpVjUUN3ME20Mlk1KG6P MVHTRW5ITVJ?
TGBC24TKB MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{P2RWlEPTB;NT61NUBvVQ>? NVrUUHBkW0GQR1XS
697 Mnj2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\veHhKSzVyPU[uNlghdk1? M1\y[nNCVkeHUh?=
J-RT3-T3-5 M4DRUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoT3TWM2OD14LkS2JI5O MlH2V2FPT0WU
KALS-1 NIXkVGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFzLUFdKSzVyPU[uOVYhdk1? MmXwV2FPT0WU
no-10 NFzhWHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTdwMkmgcm0> NH71cYlUSU6JRWK=
SK-NEP-1 MlWzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFX4OIhKSzVyPUiuO|khdk1? MVvTRW5ITVJ?
L-540 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTFyLkSyJI5O NYfte4RJW0GQR1XS
JiyoyeP-2003 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGPBOppKSzVyPUGwMlk1KG6P MX7TRW5ITVJ?
HH MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTFzLkO5JI5O M3nZN3NCVkeHUh?=
SR NEjNW|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXBSWNKSzVyPUGxMlQ2KG6P NEi4NFJUSU6JRWK=
QIMR-WIL NXfoPGkxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVy4O|FXUUN3ME2xNU45PSCwTR?= Mo\WV2FPT0WU
A4-Fuk MluyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\vTWM2OD1zMz6xNkBvVQ>? NXnaWJk{W0GQR1XS
CESS M{XCb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnTvTWM2OD1zMz6xN{BvVQ>? MkXxV2FPT0WU
KE-37 NUTtOXVzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlzlTWM2OD1zNj6wO{BvVQ>? NWTPdm1WW0GQR1XS
SK-UT-1 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTF4LkixJI5O NHPUdnBUSU6JRWK=
SIG-M5 M4jsWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHTEPVJKSzVyPUG3MlI2KG6P MXHTRW5ITVJ?
HT NWTBWmNCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTF5Lk[gcm0> Ml7CV2FPT0WU
DEL MmPPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGrPeFJKSzVyPUG3Mlk6KG6P NHyyUXNUSU6JRWK=
SK-PN-DW M4HJT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRTJyLkKzJI5O Mn6yV2FPT0WU
RPMI-8402 NHjpcHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlHGTWM2OD1{MT63O{BvVQ>? Ml3RV2FPT0WU
RPMI-6666 NFjxOIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{XreGlEPTB;MkSuOFIhdk1? Ml;DV2FPT0WU
NCI-H720 MnfCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1rZdGlEPTB;MkWuOFEhdk1? M{L6fHNCVkeHUh?=
EW-16 NX\5OW11T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTJ4Lki3JI5O NXT3XlFlW0GQR1XS
BL-70 M3G2c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnm3TWM2OD1{OD6zPEBvVQ>? NFnSXI9USU6JRWK=
SF126 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1vMTGlEPTB;M{CuN|ghdk1? MYrTRW5ITVJ?
BC-1 Mn;hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVS3eVVlUUN3ME2zNU4zPiCwTR?= M{jLTnNCVkeHUh?=
MHH-PREB-1 NFTtdZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTN{LkS0JI5O NF7Fe41USU6JRWK=
A101D NIq2TmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\NW5h{UUN3ME2zNk43OiCwTR?= MWrTRW5ITVJ?
NMC-G1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEe0T2NKSzVyPUOzMlY4KG6P MnezV2FPT0WU
LB1047-RCC M3rDTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{DMSWlEPTB;M{SuOlkhdk1? M13Ze3NCVkeHUh?=
EM-2 M1LQ[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkTHTWM2OD1|OD61N{BvVQ>? M1H6O3NCVkeHUh?=
COLO-684 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1fFbWlEPTB;M{muPEBvVQ>? M2nYVnNCVkeHUh?=
Becker NIDyNHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHDe5RKSzVyPUSxMlA2KG6P NYjtdGNGW0GQR1XS
BL-41 NYjufGVWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4HSRWlEPTB;NEOuOlYhdk1? NV:y[FUyW0GQR1XS
MDA-MB-134-VI NFqwO4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUfRdHY2UUN3ME20OE4xOiCwTR?= NVHOfmZtW0GQR1XS
L-363 Mm[3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;3UmlEPTB;NESuO|Mhdk1? MV;TRW5ITVJ?
ECC4 NGTaRpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\UPXZKSzVyPUS0Mlc5KG6P NG\UOm1USU6JRWK=
A388 NIHmdVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDCVpV7UUN3ME20OE45OiCwTR?= MljhV2FPT0WU
HEL M3vpcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTR7Lke5JI5O MXnTRW5ITVJ?
RKO Mlm2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWnHO5U3UUN3ME21NE4zQSCwTR?= NWXZRnBQW0GQR1XS
KINGS-1 MoXSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWrvN4hGUUN3ME21NU42PSCwTR?= M4rSb3NCVkeHUh?=
EB-3 M3XWNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkTYTWM2OD13Mj62O{BvVQ>? MVLTRW5ITVJ?
ARH-77 M{DhW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljxTWM2OD13Mj64JI5O MlfzV2FPT0WU
GCIY NV\mVIhMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33LNmlEPTB;NUOuOFYhdk1? MlPNV2FPT0WU
NCI-H1304 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTV5LkKyJI5O NGfEPVZUSU6JRWK=
KARPAS-299 M{PHc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXTNOGdLUUN3ME22NU45OiCwTR?= MkDhV2FPT0WU
IA-LM MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{H5UWlEPTB;NkiuNVMhdk1? NFPTcYJUSU6JRWK=
GI-1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTdyLkO5JI5O NILq[ZdUSU6JRWK=
TE-11 NXe4TZQ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{i5PGlEPTB;N{euNVchdk1? NXG1RZVbW0GQR1XS
LS-411N NUPQSIdpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFzrUG1KSzVyPUe3MlU4KG6P NFK0dI1USU6JRWK=
no-11 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFG2U4NKSzVyPUizMlI1KG6P MWPTRW5ITVJ?
MV-4-11 NYDBcnNLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3v4[GlEPTB;OEOuO|Mhdk1? MkfJV2FPT0WU
BV-173 NHTC[GdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;IRllVUUN3ME24N{46PyCwTR?= M3m4SnNCVkeHUh?=
CMK MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGfmTolKSzVyPUi0MlE3KG6P NXzEO|FIW0GQR1XS
LC4-1 NEPmXm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTh4LkeyJI5O Ml;LV2FPT0WU
COR-L279 M13RWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3PWXGlEPTB;OEeuNlUhdk1? M2e1TXNCVkeHUh?=
NCI-H209 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEnCR2FKSzVyPUi3MlQyKG6P M4HhSXNCVkeHUh?=
Raji M2fYR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHXieJBKSzVyPUi5MlczKG6P MnvqV2FPT0WU
LB996-RCC NWTifHppT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1PoT2lEPTB;OUOuOFMhdk1? NYXzTnhWW0GQR1XS
NCI-H526 NWjCSFRVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUK2S4l2UUN3ME25N{42QSCwTR?= NF\kfVdUSU6JRWK=
KGN NFPyPVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{XJXGlEPTB;OU[uNlkhdk1? NIHWfJZUSU6JRWK=
MOLT-4 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4i2NmlEPTB;OU[uO|khdk1? NFO1SWdUSU6JRWK=
PF-382 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonhTWM2OD17Nj63PUBvVQ>? MlHPV2FPT0WU
BC-3 M4OwSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTl7LkG4JI5O NEPSZlFUSU6JRWK=
KARPAS-422 M{nsOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\vNldKSzVyPUGwNk4xQSCwTR?= MXXTRW5ITVJ?
SBC-1 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{XySmlEPTB;MUC3Mlc2KG6P M1\RfXNCVkeHUh?=
LC-1F MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1r0PWlEPTB;MUC4MlA2KG6P MY\TRW5ITVJ?
GB-1 NWTHW4VPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVTBUpVpUUN3ME2xNFkvODJibl2= NIPPW29USU6JRWK=
SNB75 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\zbZpKSzVyPUGxPU43QSCwTR?= NEnJcnZUSU6JRWK=
BB65-RCC MmTXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTFzOT65N{BvVQ>? NUXZdVBzW0GQR1XS
NCI-N87 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\VcWlEPTB;MUKxMlk5KG6P MmfUV2FPT0WU
IST-MEL1 NFPMNlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2DDcGlEPTB;MUKyMlM5KG6P M{DYOXNCVkeHUh?=
HOP-62 NWPjO|lOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVGyXXl1UUN3ME2xNlYvQDlibl2= NXPNdHlwW0GQR1XS
ACN M1HyOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTF2Nj63OUBvVQ>? MXnTRW5ITVJ?
DMS-114 NF[ycYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoS4TWM2OD1zNUCuOlchdk1? M1q3XXNCVkeHUh?=
MLMA MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE\CNmhKSzVyPUG1PU45QCCwTR?= NGHnVYVUSU6JRWK=
HT-144 MofIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnTtTWM2OD1zNkWuOFMhdk1? NFnsNHVUSU6JRWK=
C2BBe1 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTF4Nz63OkBvVQ>? NGrF[lFUSU6JRWK=
L-428 NHjmO|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGS3VFNKSzVyPUG3O{44KG6P MljKV2FPT0WU
DU-4475 M2LiV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWnZcZh5UUN3ME2xPFcvPjhibl2= NWfDdG5kW0GQR1XS
CP67-MEL MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnr1TWM2OD1zOUmuN|ghdk1? Ml2xV2FPT0WU
MEG-01 M{\sU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\Ee5RKSzVyPUKwNU46PiCwTR?= NHyzVWFUSU6JRWK=
IST-SL2 MnnnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVLLS3RiUUN3ME2yNFgvPjNibl2= NF3OUIRUSU6JRWK=
ES8 NEXSWYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTJ{NT65OEBvVQ>? M3vCZXNCVkeHUh?=
COLO-800 NXq3cZZjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2PvNmlEPTB;MkO1MlI5KG6P NWjBPZRnW0GQR1XS
MFH-ino MlfpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVnZXItGUUN3ME2yN|UvQDRibl2= MljBV2FPT0WU
OVCAR-4 M17MNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\xeWlEPTB;MkO3MlI1KG6P Mn3XV2FPT0WU
PSN1 MmTkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkjJTWM2OD1{NEKuO|Ehdk1? MYLTRW5ITVJ?
EW-12 NYrqVYlyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHOSlVyUUN3ME2yOFMvOSCwTR?= MUTTRW5ITVJ?
HCC1599 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFLq[IRKSzVyPUK2NU41PyCwTR?= NYm3e|lyW0GQR1XS
SJSA-1 NUXjXmxET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTJ5MT60OkBvVQ>? Mnf2V2FPT0WU
ST486 M3u5XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmnJTWM2OD1{OU[uNVQhdk1? NInMOW9USU6JRWK=
NOMO-1 M2P3[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWrjeJVmUUN3ME2zNFAvOjFibl2= M1T3Z3NCVkeHUh?=
MN-60 NFywTZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTNyNT6zNkBvVQ>? MYfTRW5ITVJ?
HCC1187 M1jYWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnWOFYzUUN3ME2zNFcvOjVibl2= MmTiV2FPT0WU
SW982 MofPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWrPNplKUUN3ME2zNVQvPzVibl2= M{nJeXNCVkeHUh?=
LB647-SCLC NFO0NVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlLYTWM2OD1|MkiuO|Ehdk1? NIriNmxUSU6JRWK=
HC-1 MmTPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jMdmlEPTB;M{O1MlUhdk1? Mn3ZV2FPT0WU
EHEB Mlm1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnmzTWM2OD1|M{euOVIhdk1? M2T0enNCVkeHUh?=
TUR Mk[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTN4Mz65OUBvVQ>? NYDMb3BPW0GQR1XS
LU-139 M3W3Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\HS4lnUUN3ME2zO|gvODJibl2= NYLYW|hnW0GQR1XS
NB1 NVTrRnVyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVfJR|UxRTN6ND60OUBvVQ>? MUjTRW5ITVJ?
BB30-HNC Mn36S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVewPGJZUUN3ME2zPFgvOzJibl2= MmT5V2FPT0WU
HAL-01 NELZVHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7CU4l1UUN3ME2zPFkvOjZibl2= MXTTRW5ITVJ?
K5 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnriTWM2OD12MUGuN|chdk1? M1ewRXNCVkeHUh?=
MZ2-MEL M2HJS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{Ppe2lEPTB;NEGzMlY1KG6P NXj4d3RHW0GQR1XS
RXF393 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXfjc3ZrUUN3ME20NVYvPDVibl2= NHHPUpJUSU6JRWK=
NCI-H1648 NVXONFl[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3vTS2lEPTB;NEG3MlU{KG6P MkLCV2FPT0WU
TE-12 NH[0OpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWf3VZEyUUN3ME20N|QvOjZibl2= NF3XdZpUSU6JRWK=
EoL-1- M1LyNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlvGTWM2OD12M{euPVghdk1? NV;XTIR[W0GQR1XS
JAR M4P5WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkfKTWM2OD12M{iuOlIhdk1? M{fHZ3NCVkeHUh?=
DSH1 NYHwUGNVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\QUJNsUUN3ME20OVgvQTFibl2= M3PoenNCVkeHUh?=
NCI-H187 MlrSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHnTUpdKSzVyPUS2Nk45OSCwTR?= MVjTRW5ITVJ?
HCE-4 M2HKV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{H4T2lEPTB;NEe3MlY3KG6P M1HPV3NCVkeHUh?=
8-MG-BA NU\2[m5kT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3THRWlEPTB;NUixMlUzKG6P M4XQWXNCVkeHUh?=
KLE NHuwdZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWP2dG1jUUN3ME21PFUvOiCwTR?= MYfTRW5ITVJ?
KNS-42 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTV6Nj64NUBvVQ>? NIrHOYZUSU6JRWK=
MSTO-211H MkTZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTZyOT63OEBvVQ>? MV7TRW5ITVJ?
GDM-1 Ml7LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYHPelFPUUN3ME22NVQvODlibl2= M4m5cXNCVkeHUh?=
TE-1 NULyenpJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1rLSGlEPTB;NkS2MlEzKG6P MmXDV2FPT0WU
BT-474 NXLmcWlET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXjueGh1UUN3ME22OFcvODZibl2= MnS3V2FPT0WU
KARPAS-45 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHfTNWdKSzVyPU[0O{43KG6P NHfGWZZUSU6JRWK=
MOLT-16 M4ToeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRTZ2Nz65N{BvVQ>? MlHRV2FPT0WU
KURAMOCHI NWK0UlhzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXkenpxUUN3ME22OVcvPTFibl2= M{HyN3NCVkeHUh?=
K-562 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmK3TWM2OD14NkmuOVEhdk1? NVTW[opbW0GQR1XS
EKVX NUmyZ2kzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVrFN4RrUUN3ME22O|IvPzFibl2= MnXtV2FPT0WU
GAK NETFOXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWPCXIM{UUN3ME22O|UvOyCwTR?= NHLJUJFUSU6JRWK=
NCI-SNU-5 NXrsZZdGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3mTWM2OD14OUCuNFEhdk1? MoLVV2FPT0WU
NCI-H2126 M1zCOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXTh[m9rUUN3ME23NlYvQDdibl2= MX;TRW5ITVJ?
CTV-1 MknhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHLPSGRKSzVyPUe0OE46KG6P NFrRTIJUSU6JRWK=
SW962 M2O5cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTd2OD60OEBvVQ>? MV;TRW5ITVJ?
MONO-MAC-6 M3TsUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jOZmlEPTB;N{W2Mlk{KG6P NEXCbYxUSU6JRWK=
NCI-H748 NVLtUpFKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGfN[GZKSzVyPUe1PE46QSCwTR?= MVTTRW5ITVJ?
NCI-H524 NFu5[o9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPDRotKSzVyPUe4NE44OyCwTR?= NH\KNIhUSU6JRWK=
LS-123 NVzI[3JtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTd7NT62PUBvVQ>? Mn;3V2FPT0WU
NB7 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\xTWM2OD16MUSuNVQhdk1? NG[yfY5USU6JRWK=
LS-1034 Mlm4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MorQTWM2OD16MkiuPVghdk1? M3TkZnNCVkeHUh?=
TE-5 MoLKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUXvbWJQUUN3ME24PFMvPTZibl2= MlLPV2FPT0WU
A704 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;aXlJKSzVyPUi5PU4yPSCwTR?= NVK3XY1lW0GQR1XS
TK10 NWjGSVZbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2n6XWlEPTB;OUG2MlA{KG6P MnnIV2FPT0WU
NCI-H345 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTl2Mz6yNkBvVQ>? MoLOV2FPT0WU
CGTH-W-1 MoHYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXt[lBKSzVyPUm0PE4yOyCwTR?= MnfSV2FPT0WU
NCI-H510A NW\qenpQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3PMd2lEPTB;OUi1MlEzKG6P MojjV2FPT0WU
NCI-H1963 NX7qcmw1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoToTWM2OD1zLkCzNlkzKM7:TR?= MnTIV2FPT0WU
SCC-3 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEnPUm1KSzVyPUGuNFM1OTRizszN M4noT3NCVkeHUh?=
EW-11 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGT2PVlKSzVyPUGuNFg4PDNizszN NVz5VHNrW0GQR1XS
CPC-N MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkTaTWM2OD1zLkC4PEDPxE1? NWHYWYZRW0GQR1XS
NCI-H1417 M2q5eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mmq5TWM2OD1zLkGyNlYh|ryP M1vUWnNCVkeHUh?=
DG-75 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M37nfGlEPTB;MT6xOlI5PSEQvF2= MojMV2FPT0WU
HD-MY-Z MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4LybmlEPTB;MT6xOlQyPiEQvF2= NF\KPJFUSU6JRWK=
ATN-1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPETWM2OD1zLkK2NlA6KM7:TR?= NYPkTYpCW0GQR1XS
KM-H2 Mle5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTFwMk[0NFgh|ryP MUfTRW5ITVJ?
NCI-H2081 NHTncGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M132XmlEPTB;MT6yOlY{PyEQvF2= NH\DcVRUSU6JRWK=
HL-60 MlrNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnHLTWM2OD1zLkK2PVU6KM7:TR?= MV;TRW5ITVJ?
DB MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXXJR|UxRTFwMkeyOFIh|ryP NVe1SW5yW0GQR1XS
NCI-H1522 NVzHW5psT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWryZmFJUUN3ME2xMlI5QDh5IN88US=> NYjoZZdVW0GQR1XS
AM-38 MnHqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoW4TWM2OD1zLkOwO|Ih|ryP NF3US4lUSU6JRWK=
NCI-H446 NWC4b2lVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnjGTWM2OD1zLkOyNVIyKM7:TR?= NF7zdm5USU6JRWK=
SU-DHL-1 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHPTWM2OD1zLkOyPFAyKM7:TR?= NVHkN2NVW0GQR1XS
NH-12 NVO1epNiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXznRmhTUUN3ME2xMlM3Ozd2IN88US=> MknkV2FPT0WU
DMS-79 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXJTWM2OD1zLkO2PFY3KM7:TR?= M3Xse3NCVkeHUh?=
NCI-H716 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MorYTWM2OD1zLkO4PVg3KM7:TR?= M2TLbnNCVkeHUh?=
ML-2 MkD2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDNTWM2OD1zLkSxOVI6KM7:TR?= MX\TRW5ITVJ?
NB10 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmPFTWM2OD1zLkS2OlMzKM7:TR?= M2DuUHNCVkeHUh?=
ONS-76 M1zTWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXTidnRoUUN3ME2xMlU{PTZ7IN88US=> NFnQOWVUSU6JRWK=
LOUCY NFnST|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NESx[YZKSzVyPUGuOVQ3PTdizszN MWnTRW5ITVJ?
SCLC-21H MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NITjXmhKSzVyPUGuOVg2QDJizszN MnHEV2FPT0WU
TGW MoKzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\VW|VKSzVyPUGuOlM6PzVizszN M3;ndHNCVkeHUh?=
LXF-289 NV61e5dET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2q1VWlEPTB;MT63N|I3QCEQvF2= M3HaTnNCVkeHUh?=
BB49-HNC M13kbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTFwN{O1PFYh|ryP NVj0XIhUW0GQR1XS
NCI-H747 M4fiPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTFwN{WzOFYh|ryP MnX6V2FPT0WU
LU-165 Mon3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIDQXFRKSzVyPUGuPFQ6QDZizszN MlrMV2FPT0WU
OMC-1 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEfuWphKSzVyPUGuPVUxPjZizszN MlLGV2FPT0WU
RCC10RGB MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4q1UWlEPTB;MT65OVgyPyEQvF2= NUHEU2l5W0GQR1XS
SW684 NIPhbWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXruPVU3UUN3ME2xMlk3ODl7IN88US=> M{fNSXNCVkeHUh?=
TE-8 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVXoRpR1UUN3ME2yMlA2PTV7IN88US=> NGXNPHFUSU6JRWK=
SK-N-DZ MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjYOnJKSzVyPUKuNVMzPzRizszN MmezV2FPT0WU
EVSA-T MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTJwMUezNVUh|ryP M3r0bnNCVkeHUh?=
KASUMI-1 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUiyfIRrUUN3ME2yMlE5QDF3IN88US=> NV\SNVNOW0GQR1XS
NKM-1 NH7xfIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX20TW9LUUN3ME2yMlI2PDd{IN88US=> MWHTRW5ITVJ?
CAL-148 M33ZRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\MTWM2OD1{LkOzOlE1KM7:TR?= MUHTRW5ITVJ?
NCI-H64 NH62bolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFi2bHlKSzVyPUKuN|QzOzJizszN NIPMWZlUSU6JRWK=
KNS-81-FD NUK5T5p6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTJwM{[2NkDPxE1? M2nlbnNCVkeHUh?=
KM12 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUK3W4FxUUN3ME2yMlQxQDN7IN88US=> MY\TRW5ITVJ?
SW954 NX3lTZhkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHjepdKSzVyPUKuOFc4PzlizszN MkHnV2FPT0WU
NCI-H1395 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTJwNUK2OFUh|ryP M4XucnNCVkeHUh?=
DJM-1 NE\1RoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{TLNGlEPTB;Mj62NFY{KM7:TR?= MkHDV2FPT0WU
COLO-668 M33EW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmLFTWM2OD1{LkiyOlk2KM7:TR?= MXzTRW5ITVJ?
NCI-H1436 NYe3UlFJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFq1cnBKSzVyPUKuPFU3OTVizszN Mlu0V2FPT0WU
LB2241-RCC M1r5fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4WwfmlEPTB;Mj64Olg{QSEQvF2= NH;wcnhUSU6JRWK=
GT3TKB NEW2WI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWL3V3kyUUN3ME2yMlg6ODV3IN88US=> NU\EOlFxW0GQR1XS
COLO-824 MlXTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHTKWlZKSzVyPUKuPFk4PjhizszN NGLYUlRUSU6JRWK=
ES1 NH7RbndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmTyTWM2OD1{Lki5PFc6KM7:TR?= MVrTRW5ITVJ?
LB771-HNC MnLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3PJPWlEPTB;Mj65NFk1PiEQvF2= M1OyUXNCVkeHUh?=
GI-ME-N NXyxWmlmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2OxeGlEPTB;Mz6wNFkxPCEQvF2= NUnXZnFlW0GQR1XS
NALM-6 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYXJR|UxRTNwMEC5N|Mh|ryP NYTxNldYW0GQR1XS
LU-134-A MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTNwMEW0NlUh|ryP MUnTRW5ITVJ?
DMS-153 NWT5cYd4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTNwMEW4NlQh|ryP MnX3V2FPT0WU
MZ1-PC M4DD[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFToflhKSzVyPUOuNFkxPzhizszN Ml;IV2FPT0WU
NCI-H1155 M{HjN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXXJR|UxRTNwMUG2NUDPxE1? NUfuVoMzW0GQR1XS
CAS-1 MlPtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIfY[49KSzVyPUOuNVM4ODdizszN MULTRW5ITVJ?
D-502MG MkXzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTNwMUSzPUDPxE1? NInXTYRUSU6JRWK=
NCI-H2141 NISz[GFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGDVe|lKSzVyPUOuNVc1PTJizszN NHLVS49USU6JRWK=
NB6 Ml\GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlPUTWM2OD1|LkG4NlU6KM7:TR?= NXfEPZRrW0GQR1XS
NCCIT NVzYTlY6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2LUS2lEPTB;Mz6yNVgxQSEQvF2= NF7ne3JUSU6JRWK=
NB69 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoriTWM2OD1|LkOxPFkyKM7:TR?= MXPTRW5ITVJ?
JVM-2 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmXXTWM2OD1|LkO2OFM{KM7:TR?= MWHTRW5ITVJ?
K052 NIDxOnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTNwM{e5Olgh|ryP NEXHNZhUSU6JRWK=
HCC2157 NHq5OVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXJOYZKSzVyPUOuOVMzOjhizszN NYjvUG9RW0GQR1XS
KMOE-2 MlPwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYHJR|UxRTNwNUSyOFIh|ryP MXjTRW5ITVJ?
SF268 NGXXRoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkfjTWM2OD1|LkexOVU1KM7:TR?= MnnxV2FPT0WU
CHP-126 MnfDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGn6U5pKSzVyPUOuO|Y1PThizszN MV\TRW5ITVJ?
CP66-MEL M4X1cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVvsXXNSUUN3ME2zMlc6ODl2IN88US=> NWHO[lQyW0GQR1XS
NCI-H69 M{jWR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTRwMEG5N|Yh|ryP NGfZ[|FUSU6JRWK=
A253 NVX6dGRYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFjGcHRKSzVyPUSuNFIyODFizszN M1HITnNCVkeHUh?=
NB14 M4S4eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTRwMUC0O|kh|ryP NGW3R5JUSU6JRWK=
NCI-H1694 Mlu4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTRwMUOxNVIh|ryP NFnwV4xUSU6JRWK=
NCI-H2196 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlfqTWM2OD12LkG3NVY6KM7:TR?= M{[5SnNCVkeHUh?=
TE-9 NFq1NJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTRwMUe1PFIh|ryP MXXTRW5ITVJ?
D-283MED NXfubXo2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTRwMUi4OEDPxE1? MXHTRW5ITVJ?
OCI-AML2 NUW5T2J2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYC0[YZUUUN3ME20MlE6PDh7IN88US=> NYT4eGg4W0GQR1XS
D-263MG MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jMO2lEPTB;ND6yNlk3OSEQvF2= MlnuV2FPT0WU
MPP-89 NHrtcIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTRwMkezNFQh|ryP M3;MNnNCVkeHUh?=
LAMA-84 NGfPfIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmfFTWM2OD12LkOwOFIyKM7:TR?= MoHsV2FPT0WU
LB373-MEL-D MnLvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTRwM{[3PFkh|ryP Mnq2V2FPT0WU
UACC-257 M2TLfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIK0PFJKSzVyPUSuN|k2OzRizszN M{PyTHNCVkeHUh?=
MC-CAR NIHqNo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4f2fWlEPTB;ND60N|k6KM7:TR?= M1HwSnNCVkeHUh?=
COLO-320-HSR MkHQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkT5TWM2OD12LkS0OFI4KM7:TR?= MXvTRW5ITVJ?
P30-OHK NYroZm1FT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4fRNGlEPTB;ND62OlU5OSEQvF2= NYfRe3pQW0GQR1XS
UACC-812 NV3WUmhqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1PSUGlEPTB;ND62PVE3OSEQvF2= MVvTRW5ITVJ?
CTB-1 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYfZUXFIUUN3ME20MlcyPTV3IN88US=> MojOV2FPT0WU
ALL-PO NFTkTWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2rBWmlEPTB;ND64OFA4PyEQvF2= NYLlTm54W0GQR1XS
SK-MEL-2 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUHPXIlwUUN3ME20Mlg3QTV3IN88US=> MknxV2FPT0WU
TC-YIK NH;RTZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\QTWM2OD12Lkm3PVQzKM7:TR?= M{jF[3NCVkeHUh?=
NCI-H1882 M{fvb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1e1OWlEPTB;NT6wNlAxOSEQvF2= M1noVnNCVkeHUh?=
MHH-CALL-2 NIjiV3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTVwMEWwOFIh|ryP M13wUHNCVkeHUh?=
U-87-MG NFTHO2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTVwMEm0OlYh|ryP MlXaV2FPT0WU
NCI-H1092 NFn4Sm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M33KbmlEPTB;NT6yOlU2PSEQvF2= NEXBdohUSU6JRWK=
TE-441-T MonPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlvDTWM2OD13LkK3PFIh|ryP MY\TRW5ITVJ?
SK-MEL-1 M{nJOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1f4cGlEPTB;NT6yPVA1PCEQvF2= NEfWTXdUSU6JRWK=
EW-22 MljiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn2yTWM2OD13LkK5OFY3KM7:TR?= MkTlV2FPT0WU
MZ7-mel NYi4enQyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoTJTWM2OD13LkSwOlkyKM7:TR?= MnzyV2FPT0WU
LP-1 M4Pwemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVzvTHBxUUN3ME21MlQyOjlzIN88US=> MXnTRW5ITVJ?
NCI-SNU-16 M3Tyb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoXQTWM2OD13Lk[0NFc1KM7:TR?= MoDxV2FPT0WU
LU-65 M2S4bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkK4TWM2OD13Lke2N|c{KM7:TR?= MmLSV2FPT0WU
CW-2 NFvPXINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFvnXWFKSzVyPUWuPFU6PTlizszN MVfTRW5ITVJ?
WSU-NHL MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{L4NWlEPTB;NT65OVE4PCEQvF2= NELRW2NUSU6JRWK=
IST-MES1 NFrUbGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVfBbIZHUUN3ME21Mlk2PDR|IN88US=> MlryV2FPT0WU
U-266 NV:zToNuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\GTFZKSzVyPUWuPVgzODJizszN NGnONW1USU6JRWK=
TALL-1 NH6xWpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlLPTWM2OD14LkG0Olg5KM7:TR?= NHLNSYtUSU6JRWK=
Calu-6 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFHQblBKSzVyPU[uNVU{OTZizszN M2DRbXNCVkeHUh?=
MMAC-SF NEjYc5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|UxRTZwMUi1OVYh|ryP MWTTRW5ITVJ?
NCI-H82 NXjkNVh6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDmSXV3UUN3ME22MlIxPDh7IN88US=> MUDTRW5ITVJ?
RS4-11 NEf0dXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGPnZmNKSzVyPU[uNlU5QTdizszN NHrTfoJUSU6JRWK=
SNU-C2B NE\Tb|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnrZTWM2OD14LkSwPVY6KM7:TR?= NVP3WHZsW0GQR1XS
BOKU MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlL6TWM2OD14LkS3OVk4KM7:TR?= NVPYXIJkW0GQR1XS
C8166 Mnj4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHn4cItKSzVyPU[uOVU6OTJizszN MnnTV2FPT0WU
D-247MG MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTdwMESzOFch|ryP M2jiUnNCVkeHUh?=
EW-18 NFzV[oRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTdwMEeyPVIh|ryP M1PrbXNCVkeHUh?=
KG-1 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUTabldsUUN3ME23MlYzPzN6IN88US=> NEXuVnhUSU6JRWK=
REH M1nqOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUewXW5yUUN3ME23MlY5OTB7IN88US=> MlfvV2FPT0WU
U-698-M MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIT5dZRKSzVyPUeuPFQ{OTVizszN MluzV2FPT0WU
KP-N-RT-BM-1 M3;ieGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\JNmVQUUN3ME23Mlk{ODJ7IN88US=> Mnq2V2FPT0WU
MS-1 NFrtWZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonnTWM2OD15Lkm2NFQyKM7:TR?= M4jpVXNCVkeHUh?=
SNU-C1 MkXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoLmTWM2OD15Lkm4NVkzKM7:TR?= M1u3[nNCVkeHUh?=
SK-MM-2 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRThwMk[wOlUh|ryP Mn35V2FPT0WU
LAN-6 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NET0RnBKSzVyPUiuN|AxODFizszN NH3hPFBUSU6JRWK=
NEC8 NUfwTHpJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRThwM{C2PVEh|ryP M1zCdXNCVkeHUh?=
NCI-H1770 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVrZfHVtUUN3ME24MlM5ODB{IN88US=> MkHsV2FPT0WU
D-336MG NVroSnB3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmC1TWM2OD16LkSwNVE3KM7:TR?= M2DwRXNCVkeHUh?=
COLO-829 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHLRWWVKSzVyPUiuOFg5PzlizszN NXPjUVJsW0GQR1XS
LS-513 M2XSR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPFb5RKSzVyPUiuOVk2QTlizszN M{XCVnNCVkeHUh?=
YT MlHxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzTXoVkUUN3ME24MlYzPDJ5IN88US=> NH;hfFJUSU6JRWK=
EW-24 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYO1OJhlUUN3ME24Mlc3PTRizszN MmLJV2FPT0WU
IST-SL1 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFHLVlZKSzVyPUiuPFY2PDNizszN M1nmcXNCVkeHUh?=
CA46 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\hXIhoUUN3ME24Mlk2ODl6IN88US=> MVTTRW5ITVJ?
NCI-H1838 NFzhd|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRThwOUi2NFIh|ryP NV7uOYJrW0GQR1XS
NCI-H719 NILzZXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXG3eoFkUUN3ME25MlI2Ojd7IN88US=> M3TVXHNCVkeHUh?=
HCE-T MnHSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33sZWlEPTB;OT6zNFg2OSEQvF2= MWDTRW5ITVJ?
A498 MlXTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NInCVnlKSzVyPUmuN|YyOjRizszN NWTxVXBYW0GQR1XS
LB831-BLC NHjUWWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYjtWnU{UUN3ME25Mlc3PTJzIN88US=> MoPhV2FPT0WU
SKM-1 Mn;qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDsTWM2OD17Lki1PVY{KM7:TR?= M3rpOXNCVkeHUh?=
THP-1 M2mzVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3zVNmlEPTB;OT65OlkyQCEQvF2= M1L1VXNCVkeHUh?=
SHP-77 Mn30S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mny2TWM2OD1zMD60NFch|ryP NGLMS2NUSU6JRWK=
EW-3 MnPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYfEc2NbUUN3ME2xNE43Ojh7IN88US=> MXLTRW5ITVJ?
KY821 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILSZWJKSzVyPUGwMlc3OyEQvF2= NViybIFbW0GQR1XS
NCI-SNU-1 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlvITWM2OD1zMT6wNlE4KM7:TR?= M4\6c3NCVkeHUh?=
HCC2218 M4[3cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX7QbndOUUN3ME2xNU4{QTh4IN88US=> MkPrV2FPT0WU
IM-9 M4[wUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTFzLkWxNFYh|ryP NYjiZo9iW0GQR1XS
NCI-H889 M2HZbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnfSTWM2OD1zMT61N|E{KM7:TR?= MX;TRW5ITVJ?
HDLM-2 M17BTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFi4fo5KSzVyPUGyMlQyPTlizszN MU\TRW5ITVJ?
LB2518-MEL Mk\mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MojDTWM2OD1zMj62PFE2KM7:TR?= M3\Ke3NCVkeHUh?=
NCI-H23 MoDIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGXERWhKSzVyPUGzMlI1OjVizszN NXvrVJhsW0GQR1XS
NB17 Mn62S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVLuPIRsUUN3ME2xN{41PTd7IN88US=> MoTiV2FPT0WU
NCI-H322M NUXiWYZsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTF2LkSwOlgh|ryP NFrNfZRUSU6JRWK=
SUP-T1 NUnaTGpPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHH1NlNKSzVyPUG0MlQyOyEQvF2= NHjyTm9USU6JRWK=
ES3 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTF3LkC3NFMh|ryP M4DScnNCVkeHUh?=
ES5 NYHKO5V4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXT2VYdpUUN3ME2xOU4xPzh5IN88US=> MmXYV2FPT0WU
NCI-H1650 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTF3LkS5O|kh|ryP NG\zc2VUSU6JRWK=
NCI-H226 MmHSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF[yO|dKSzVyPUG1Mlg4PjhizszN NFy5SWlUSU6JRWK=
COR-L88 NVTTWJlmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFnINpNKSzVyPUG2MlMyPCEQvF2= NFGwOoVUSU6JRWK=
SCC-15 Mm\ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HLSmlEPTB;MU[uN|g3QSEQvF2= M1zmcnNCVkeHUh?=
GOTO NEnU[JVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NELD[pdKSzVyPUG2MlQ4QTNizszN MWDTRW5ITVJ?
SIMA NI[3NnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTF4LkS4NFIh|ryP MVHTRW5ITVJ?
NCI-H1299 M1zifmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlvXTWM2OD1zNz6xOVkyKM7:TR?= MY\TRW5ITVJ?
NCI-H1581 NITUdG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlzhTWM2OD1zNz60NlE6KM7:TR?= NYLsc2hlW0GQR1XS
MHH-NB-11 NHnBNY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmDaTWM2OD1zNz65Olg{KM7:TR?= NIHBfXZUSU6JRWK=
MFM-223 M4jsemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTF6LkC1N|gh|ryP NFTQfG9USU6JRWK=
ES7 M2P0Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFj4cW5KSzVyPUG4MlU1OzFizszN NYe4bmFuW0GQR1XS
JVM-3 NF2xdFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2jpWWlEPTB;MUiuO|E4KM7:TR?= M4H1OXNCVkeHUh?=
RL NEXHW|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTJyLkO4PEDPxE1? NFPPdXNUSU6JRWK=
EC-GI-10 NX7CdHl5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTJzLkKwOFEh|ryP NYjZToR3W0GQR1XS
LNCaP-Clone-FGC M{jSemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnLNTWM2OD1{MT62O|Y5KM7:TR?= MW\TRW5ITVJ?
IMR-5 NInhOVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEH1[3ZKSzVyPUKxMlg1QTRizszN MV\TRW5ITVJ?
KP-N-YS NVHJN5pwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTJzLki3OUDPxE1? NWf2bZFsW0GQR1XS
Mo-T MkezS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX;QVJVwUUN3ME2yNk4zOTh3IN88US=> M2nOfXNCVkeHUh?=
NCI-H128 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFK0XpdKSzVyPUKzMlU5PTNizszN NIK2V5RUSU6JRWK=
RH-1 NFP1PI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRTJ|Lke4OlYh|ryP Mn\RV2FPT0WU
NCI-H2171 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFnVUHJKSzVyPUK0MlI1QDVizszN NITE[4VUSU6JRWK=
RPMI-8866 NXzRUJZvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2qzWmlEPTB;Mk[uO|QzKM7:TR?= M2OxbnNCVkeHUh?=
SK-N-FI NIPUSFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTJ5LkO4NVEh|ryP NIHkOnJUSU6JRWK=
LOXIMVI NEf2O5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\IWmpGUUN3ME2yO{45ODVzIN88US=> NETqZ2lUSU6JRWK=
P31-FUJ NYPOUmVOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFr2NZdKSzVyPUOxMlU{PzRizszN MUjTRW5ITVJ?
KMS-12-PE MnPaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTR7LkWzNFIh|ryP MXTTRW5ITVJ?

... Click to View More Cell Line Experimental Data

In vivo試験 Treatment with Rapamycin in vivo specifically blocks targets known to be downstream of mTOR such as the phosphorylation and activation of p70S6K and the release of inhibition of eIF4E by PHAS-1/4E-BP1, leading to complete blockage of the hypertrophic increases in plantaris muscle weight and fibre size. [4] Short-term Rapamycin treatment, even at the lowest dose of 0.16 mg/kg, produces profound inhibition of p70S6K activity, which correlates with increased tumor cell death and necrosis of the Eker renal tumors. [5] Rapamycin inhibits metastatic tumor growth and angiogenesis in CT-26 xenograft models by reducing the production of VEGF and blockage of VEGF-induced endothelial cell signaling. [6] Rapamycin treatment at 4 mg/kg/day significantly reduces tumor growth of C6 xenografts, and tumor vascular permeability. [7]
臨床試験 A Phase II study of Rapamycin to erase angiofibromas in patients with Tuberous Sclerosis Complex (TSC) is currently ongoing.
特集

プロトコル (参考用のみ)

キナーゼアッセイ:

[1]

Immunoblotting for the mTOR kinase assay HEK293 cells are plated at 2-2.5×105 cells/well of a 12-well plate and serum-starved for 24 hours in DMEM. Cells are treated with increasing concentrations of Rapamycin (0.05-50 nM) for 15 minutes at 37 °C. Serum is added to a final concentration of 20% for 30 minutes at 37 °C. Cells are lysed, and cell lysates are separated by SDS-PAGE. Resolved proteins are transferred to a polyvinylidene difluoride membrane and immunoblotted with a phosphospecific primary antibody against Thr-389 of p70 S6 kinase. Data are analyzed using ImageQuant and KaleidaGr

細胞アッセイ:

[3]

細胞株 U87-MG, T98G, and U373-MG
濃度 Dissolved in DMSO, final concentrations ~25 μM
反応時間 72 hours
実験の流れ

Cells are exposed to various concentrations of Rapamycin for 72 hours. For the assessment of cell viability, cells are collected by trypsinization, stained with trypan blue, and the viable cells in each well are counted. For the determination of cell cycle, cells are trypsinized, fixed with 70% ethanol, and stained with propidium iodide using a flow cytometry reagent set. Samples are analyzed for DNA content using a FACScan flow cytometer and CellQuest software. For apoptosis detection, cells are stained with the terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) technique using an ApopTag apoptosis detection kit. To detect the development of acidic vesicular organelles (AVO), cells are stained with acridine orange (1 μg/mL) for 15 minutes, and examined under a fluorescence microscope. To quantify the development of AVOs, cells are stained with acridine orange (1 μg/mL) for 15 minutes, removed from the plate with trypsin-EDTA, and analyzed using the FACScan flow cytometer and CellQuest software. To analyze the autophagic process, cells are incubated for 10 minutes with 0.05 mM monodansylcadaverine at 37 °C and are then observed under a fluorescence microscope.

動物実験:

[7]

動物モデル Athymic Nu/Nu mice inoculated subcutaneously with VEGF-A-expressing C6 rat glioma cells
製剤 Dissolved in solvent solution (0.2% carboxymethylcellulose and 0.25% Tween-80 in sterile H2O)
投薬量 ~4 mg/kg/day
投与方法 Injection i.p.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDogMonkeyBaboon
Weight (kg)0.020.151.80.40.0810312
Body Surface Area (m2)0.0070.0250.150.050.020.50.240.6
Km factor361285201220
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

参考

化学情報

Download Rapamycin (Sirolimus) SDF
分子量 914.18
化学式

C51H79NO13

CAS No. 53123-88-9
保管 2年-20℃
6月-80℃in solvent
別名 AY 22989,NSC-2260804
溶解度 (25°C) * In vitro DMSO 20 mg/mL (21.87 mM)
<1 mg/mL (<1 mM)
エタノール <1 mg/mL (<1 mM)
In vivo 2% DMSO+30% PEG 300+5% Tween 80+ddH2O 5mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
化学名 (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylethyl]-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone

文献中の引用 (62)

技術サポート&よくある質問(FAQ)

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

電話番号: +1-832-582-8158 Ext:3月曜日〜金曜日 9:00 AM–5:00 PM (米国中部標準時)

他の質問がある場合は、お気軽くお問合せください。

* 必須

Related mTOR 阻害剤

  • MHY1485

    MHY1485 is a potent, and cell-permeable mTOR activator, and also potently inhibits autophagy.

  • CHIR-99021 (CT99021)

    CHIR-99021(CT99021)は、GSK-3αとGSK-3β阻害剤で、IC50 がそれぞれ 10 nM と 6.7 nMである。

  • Dorsomorphin

  • Afuresertib (GSK2110183)

    Afuresertib (GSK2110183) is a potent, orally bioavailable Akt inhibitor with Ki of 0.08 nM, 2 nM, and 2.6 nM for Akt1, Akt2, and Akt3, respectively. Phase 2.

  • Everolimus (RAD001)

    Everolimus (RAD001) は、1.6-2.4nMのIC50によるFKBP12のmTOR阻害剤です。

  • AZD8055

    AZD8055は、0.8nMのIC50によるmTORの新しいATP競争的阻害剤です。

    Features:First drug to inhibit both types of mTOR protein.

  • Torin 1

    Torin1は、mTORの強力な阻害剤で、IC50 が 2-10 nMです。

  • Temsirolimus (CCI-779, NSC 683864)

    Temsirolimus (CCI-779, NSC 683864)は、特定のmTOR阻害剤で、IC50 が 1.76 μM。

  • INK 128 (MLN0128)

    INK 128 (MLN0128)は、有力で選択的なmTOR 阻害剤で、 IC50 が 1 nMです。

最近チェックしたアイテム

Tags: Rapamycin (Sirolimus)を買う | Rapamycin (Sirolimus)供給者 | Rapamycin (Sirolimus)を購入する | Rapamycin (Sirolimus)費用 | Rapamycin (Sirolimus)生産者 | オーダーRapamycin (Sirolimus) | Rapamycin (Sirolimus)代理店
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
お問い合わせ